Fundraising Fox

TORL BioTherapeutics

Culver City, US · 1 known investors

Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.

Biotech

Founders & leadership

MA
Mark AllesExecutive Officer, Director
MA
Mark AttanasioDirector
DL
David LicataExecutive Officer, Director
NO
Neil O'BrienDirector
AS
Amit SinhaDirector
LS
Lynn SeelyDirector
DS
Dennis SlamonDirector

Investors · 1

OCV PartnersLos Angelesvia Chris Bostick · led

Reported raises · per SEC filings

Form D private placements
▶$158.3MraisedApr 2024 · 52 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark AllesExecutive Officer, Director
  • Mark AttanasioDirector
  • David LicataExecutive Officer, Director
  • Neil O'BrienDirector
  • Amit SinhaDirector
  • Lynn SeelyDirector
  • Dennis SlamonDirector
Offering amount
$158.3M
Amount sold
$158.3M
First sale
Apr 2024
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.